Shanghai Fosun Pharmaceutical (600196) Stock Price, News, Quotes-Moomoo

CN Stock MarketDetailed Quotes

600196 Shanghai Fosun Pharmaceutical

Watchlist

23.81
+0.15+0.63%

Market Closed Jan 24 15:00 CST

63.60BMarket Cap30.10P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Shanghai Fosun Pharmaceutical Arm Gets Registration for Anti-Bronchospasm Drug in China
MT NewswiresJan 24 07:49 ET
Express News | Shanghai Fosun Pharma - Drug Registration Applications of Levosalbutamol Hydrochloride Nebuliser Solution Was Accepted by Nmpa
ReutersJan 24 05:41 ET
On January 24, FOSUN PHARMA (02196) spent approximately 3.3504 million Hong Kong dollars to repurchase 0.251 million shares.
FOSUN PHARMA (02196) announced that on January 24, 2025, it spent approximately 3.3504 million Hong Kong dollars to repurchase 25....
Zhitong FinanceJan 24 05:20 ET
FOSUN PHARMA (600196.SH): The pharmaceutical registration application for levalbuterol hydrochloride inhalation solution has been accepted.
FOSUN PHARMA (600196.SH) released a notice that the company's holding subsidiary, FOSUN PHARMA (Xuzhou) Co., Ltd. has salt...
Zhitong FinanceJan 24 04:27 ET
Fosun Pharmaceutical to Repurchase Shares in Hong Kong, Shanghai
MT NewswiresJan 23 05:19 ET
Major rating｜Citi: Downgraded FOSUN PHARMA's Target Price to HKD 15.8. The impact of centralized procurement is controllable.
Credit Lyonnais published a report indicating that the resolution for FOSUN PHARMA to privatize HENLIUS was not approved by the shareholders, thus HENLIUS remains a publicly listed subsidiary of FOSUN PHARMA holding 59.6% shares, and serves as its innovation center. Additionally, although the province of Anhui's centralized procurement of biosimilars is still in its initial stages, the bank believes its impact is manageable as FOSUN PHARMA's key biosimilar products should be competitive. The bank assigns FOSUN PHARMA an "outperform" rating, lowering the Target Price from HKD 17.2 to HKD 15.8, and reducing its revenue forecast by 0.7% to 3.1%, along with the earnings forecast.
Gelonghui FinanceJan 23 04:43 ET

Comments

Spinee

Jun 24, 2024 21:45

HSI Opens Up 60 pts; LI AUTO & NIO Advance, as HENLIUS Rockets 21%

Hong Kong stocks opened higher in the morning. $Hang Seng Index (800000.HK)$opened 60 points or 0.3% higher at 18,088. $Hang Seng China Enterprises Index (800100.HK)$ opened 22 points or 0.3% higher at 6,463. $Hang Seng TECH Index (800700.HK)$ opened 11 points or 0.3% higher at 3,689.
$FOSUN PHARMA (02196.HK)$ proposed to privatise $HENLIUS (02696.HK)$ at $24.6 per share. HENLIUS opened rocketing 21.3% at $22.85, while FOSUN PHARMA opened lifting 1.2% at...

Spinee

Apr 25, 2023 11:34

HSI Slides 342 Pts; Techs & Pharmas Gloom

$Hang Seng Index (800000.HK)$ concluded the day at 19,617, down 342 pts or 1.7%. $Hang Seng China Enterprises Index (800100.HK)$ sagged 131 pts or 2% to 6,601. $Hang Seng TECH Index (800700.HK)$ faded 137 pts or 3.5% to 3,824. The turnover aggregated $106.657 billion.
Techs slid as the market continued to be watchful of the Sino-US relations:
$BABA-W (09988.HK)$ dived 3.2% to $84.1.
$TENCENT (00700.HK)$ sank 1.9% to $338.4.
$MEITUAN-W (03690.HK)$ , $XIAOMI-W (01810.HK)$ , ...

Senorita Earnings

Mar 1, 2023 23:54

Columns Expert Meeting Minutes | Seven Development Trends of the China Medical Aesthetics Industry

Core point
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...

Spinee

Dec 14, 2022 00:12

The domestic COVID-19 oral drug Azifodine is planned to be sold online, and $FOSUN PHARMA (02196.HK)$ shares were opened 12% higher to 29 yuan.
$Pfizer (PFE.US)$ $AIM VACCINE (06660.HK)$

Spinee

Dec 6, 2022 21:36

In terms of allocation of Chinese stocks, it is suggested to focus on three main lines:

First, under the optimization of epidemic prevention, the repair market of damaged plates in the early stage, such as biomedical, aviation, wine travel and other plates;
Second, under the demand of stable growth, the industry policy margin is loose, such as the real estate industry chain and the Internet and other industries;
Third, under the theme of security for a long time, energy security, self contro...